尿毒症继发医院感染的危险因素分析

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo analyze and explore the risk factors of secondary nosocomial infection in uremia and to provide reference for clinical treatment and nursing of uremia.MethodsThe clinical data of 184 uremic patients treated in our hospital from December 2014 to October 2017 were retrospectively analyzed.According to whether hospital infection occurred,all the patientswere divided into the infection group(n=92)and the non-infection group(n=92).And the clinical symptoms and signs of the two groups of patientswere analyzed and compared.Logistic regression was used to analyze the risk factors of nosocomial infection secondary to uremia.ResultsA total of 184 cases of uremic patients sent samples 243 cases,the positive detection rate was 67.08%.Pathogenic bacteria were mainly Klebsiella pneumoniae(31.90%),Pseudomonas aeruginosa(26.38%)and Escherichia coli(15.34%).Secondly,Logistic regression analysis showed that age,presence of dialysis,hyperglycemia,high serum creatinine and high serum albumin were the risk factors of secondary nosocomial infections in uremic patients(OR＞1,P＜0.05).BMI≥24 kg/m2was the protective factor of secondary nosocomial infection in uremic patients(OR＜1,P＜0.05).ConclusionSecondary nosocomial infections in uremia are affected bymany factors.It is suggested that targeted interventions should bemade according to the above risk factors and protective factors so as to reduce the incidence of infection.

Key words： Uremia Nosocomial infection Influencing factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Zhi-peng
	SHENMei-fang
	CHEN Dong

Cite this article:

CHEN Zhi-peng,SHENMei-fang,CHEN Dong. Analysis of risk factors of nosocom ial infection secondary to urem ia[J]. 中国当代医药, 2018, 25(16): 78-80.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I16/78

[13]	梁虹，吴煌福，陈文，等.尿毒症患者肺部感染综合护理干预的效果分析[J].中华医院感染学杂志，2016，26（3）：690-691.
[14]	方帆.尿毒症患者导管相关性血流感染的危险因素及致病菌分析[D].重庆：重庆医科大学，2016：14.
[1]	刘法芹，李述真.老年尿毒症维持性血液透析患者C-反应蛋白、营养状态与感染的关系[J].中国老年学杂志，2014，34（23）：6653-6655.
[2]	陈学波，胡玉纹.尿毒症维持性血液透析患者C-反应蛋白及营养状态与感染的关系[J].中华医院感染学杂志，2014，24（5）：1181-1183.
[3]	中华人民共和国卫生部.医院感染诊断标准[M].北京：中华人民共和国卫生部，2001：10-12.
[4]	吴歌，高丹，贾晓媛，等.尿毒症血液透析患者医院感染危险因素分析[J].中华医院感染学杂志，2014，24（2）：393-395.
[5]	梁虹，高海娥，李飞，等.糖尿病肾病尿毒症患者尿路感染危险因素分析与预防[J].中华医院感染学杂志，2016，26（5）：1056-1058.
[6]	孙旭震，肖英，张红霞，等.追踪方法对尿毒症血液透析患者医院感染的预防控制效果研究[J].中华医院感染学杂志，2016，26（3）：687-689.
[7]	江强，陶一鸣，陈朝荣，等.尿毒症患者结核分枝杆菌感染的临床特点分析[J].中华医院感染学杂志，2017，27（17）：3890-3892，3900.
[8]	李博，王立华，董红业，等.尿毒症住院患者感染部位与病原菌分析[J].中华医院感染学杂志，2017，27（5）：1011-1014.
[9]	何援军，金劼，潘晓红，等.尿毒症患者持续血液透析医院感染血清炎症指标的变化研究[J].中华医院感染学杂志，2015，25（12）：2652-2654.
[10]	李莉红，邓孝陵，陈以莲，等.尿毒症维持性血液透析患者肺部感染病原菌分布与耐药性分析[J].中华医院感染学杂志，2015，25（17）：3875-3877.
[11]	卢蓉，刘俊峰，金威，等.尿毒症患者肺部感染的危险因素分析[J].中华医院感染学杂志，2015，25（14）：3226-3228.
[12]	谢海萍，暨利军，徐丽丽，等.糖尿病肾病尿毒症患者尿路感染危险因素分析与临床预防策略研究[J].中华医院感染学杂志，2016，26（24）：5610-5612.
[15]	Gudbrandsdottir S，Bir gens HS，Frederiksen H，et al.Rituximab and dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia[J].Blood，2013，121（11）：1976-1981.
[16]	Huang SS.Catheter-a ssociated urinary tract infections turn-inary tract infections turning the tide[J].N Engl JMed，2016，374（22）：2168-2169.
[17]	Yoshida T，Kato J，Inoue I，et al.Cancer development based on chronic active gastritis and resulting gastric atrophy as asssed by serum levels of pepsinogen and Helicobacter pyloriantibody titer[J].Int JCancer，2014，134（6）：1445-1457.
[18]	Stenzelius K，Laszlo L，Madeja M，et al.Catheter associated urinary tract infections and other infections in patients hospirealized for acute stroke：aprospective cohort study of two diff erent silicone catheters[J].Scand JUrol，2016（21）：1-6.
[19]	侯静，刘进，陈昕，等.尿毒症患者医院感染病原菌分布及耐药性分析[J].中国老年学杂志，2015，35（19）：5588-5589.
[20]	Yoshida T，Kato J，Inoue I，et al.Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pyloriantibody titer[J].Int JCancer，2014，134（6）：1445-1457.